Search company, investor...

Predict your next investment

Venture Capital
missionbaycapital.com

Investments

61

Portfolio Exits

11

Funds

4

Partners & Customers

1

About Mission Bay Capital

Mission Bay Capital, is an independent venture firm focused on making pivotal, early-stage investments in bioscience companies emerging from the University of California. Mission Bay Capital is fueling breakthrough bioscience technologies to meet societyÂâÂÂs challenges while also helping to boost the California economy.

Headquarters Location

953 Indiana Street

San Francisco, California, 94107,

United States

415-240-4970

Want to inform investors similar to Mission Bay Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Mission Bay Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Mission Bay Capital in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Latest Mission Bay Capital News

Astellas And MBC BioLabs Announce Astellas Future Innovator Prize To Help Biotech Start-Ups Accelerate Early Drug Discovery And ...

Sep 22, 2022

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators Tokyo and San Francisco, CA /PRNewswire/ - Astellas Venture Management LLC (President: William Watt, Ph.D., "AVM"), a wholly-owned venture capital subsidiary of Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), and Mission Bay Capital BioLabs ("MBC BioLabs"), a life-science incubator, today announced their collaboration on the "Astellas Future Innovator Prize" formerly known as the Astellas Golden Ticket competition. Building on over three successful years, the competition offers entrepreneurial scientists or emerging biotechnology start-ups one year's priority usage of MBC BioLabs' state-of-the-art lab facility and access to Astellas' research and development (R&D) capabilities and business leaders. With a shared commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide, AVM and MBC BioLabs are continuing their partnership to support scientists and early-stage companies to accelerate their novel therapeutic programs, modalities or platforms. The 2022 competition will prioritize innovative research that compliment Astellas' Focus Area Approach and pipeline. "We are truly thrilled to host the Astellas Future Innovator Prize again this year," said William Watt, President, AVM. "Through our long-term collaboration with MBC BioLabs, we aim to create an environment that encourages innovation to thrive. The Astellas Future Innovator Prize enables us to provide biotech companies with expertise and capabilities to turn an innovative idea into a real solution, which could transform the lives of patients in need around the world." "We are pleased to continue our partnership with Astellas to uncover the innovators of tomorrow," said Douglas Crawford, MBC BioLabs General Manager. "The past winners of the Astellas Future Innovator Prize show what can be achieved by combining Astellas' support, advice and expertise with our laboratory incubator, and we are excited to see the result of our ongoing collaboration." Entrepreneurial scientists, emerging life-science and biotechnology start-ups have until November 4, 2022 to enter the Astellas Future Innovator Prize. About the Astellas Future Innovator Prize at MBC BioLabs Astellas is offering up to two prizes for pioneering scientists with innovative research that complements Astellas' areas of interest in alignment with its Focus Area Approach and pipeline, including Blindness & Regeneration, Mitochondria, Genetic Regulation, Immuno-Oncology, Cell Therapy, and other areas. Companies awarded an Astellas Future Innovator Prize will gain one year's priority admission or renewal to MBC BioLabs' state-of-the-art laboratory and access to Astellas' R&D scientists and business leaders. The competition is open from September 19 to November 4, 2022. Entrepreneurial scientists, emerging life-science or biotechnology start-ups should submit their non-confidential company presentation, including a one-page executive summary, to https://www.astellas.com/en/astellasfutureinnovator/san-francisco2022 to be considered. The decision to award any Astellas Future Innovator Prize and the assessments underlying such decision, are solely within the judgment of Astellas and are not subject to any objection or appeal. The 2021 Astellas Future Innovator Prize winners were Vcreate and Weatherwax Biotechnologies, chosen for the potential of their innovations to deliver therapeutic advances for unmet medical needs and their potential synergy with Astellas' Focus Area Approach. For further information, please go to: https://www.astellas.com/en/astellasfutureinnovator/ , where you can also find submission guidance for your non-confidential company presentation and executive summary. About Astellas Venture Management LLC AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients. For over 15 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research. For more information, please visit our website at https://www.astellas.com/en/astellasfutureinnovator/ . About Astellas Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at https://www.astellas.com/en . About MBC BioLabs MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, MBC BioLabs allows companies to be fast, focused, and frugal. It has three sites: one in the Dogpatch neighborhood in San Francisco and two campuses in San Carlos, California. Each site has a complete molecular biology core facility that allows companies to do experiments on day one. MBC BioLabs has partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Since opening in 2013, MBC BioLabs has helped launch and grow 290 companies. These companies have brought 58 programs to the clinic, produced 13 approved diagnostics, and raised over $14 billion. Cautionary Notes In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice. Source: Astellas Pharma Inc.

Mission Bay Capital Investments

61 Investments

Mission Bay Capital has made 61 investments. Their latest investment was in Telo Therapeutics as part of their Seed VC on June 6, 2021.

CBI Logo

Mission Bay Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/22/2021

Seed VC

Telo Therapeutics

$4.71M

Yes

2

3/23/2021

Series A

Asher Bio

$55M

Yes

12

2/9/2021

Series A - III

Invenio Imaging

$3.04M

No

1

9/14/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

7/29/2020

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/22/2021

3/23/2021

2/9/2021

9/14/2020

7/29/2020

Round

Seed VC

Series A

Series A - III

Series A

Seed VC

Company

Telo Therapeutics

Asher Bio

Invenio Imaging

Subscribe to see more

Subscribe to see more

Amount

$4.71M

$55M

$3.04M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

12

1

10

10

Mission Bay Capital Portfolio Exits

11 Portfolio Exits

Mission Bay Capital has 11 portfolio exits. Their latest portfolio exit was ViewPoint Therapeutics on September 28, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/28/2022

Acquired

$99M

2

7/23/2021

IPO

$99M

Public

10

5/27/2021

Acq - Pending

$99M

2

3/2/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/20/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/28/2022

7/23/2021

5/27/2021

3/2/2021

6/20/2019

Exit

Acquired

IPO

Acq - Pending

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

10

2

10

10

Mission Bay Capital Fund History

4 Fund Histories

Mission Bay Capital has 4 funds, including Mission Bay Capital III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

9/16/2019

Mission Bay Capital III

Early-Stage Venture Capital

Closed

$60M

1

5/2/2015

Mission Bay Capital II

Subscribe to see more

Subscribe to see more

$99M

10

10/28/2009

QB3 Garage

Subscribe to see more

Subscribe to see more

$99M

10

Life Science Fund

10

Closing Date

9/16/2019

5/2/2015

10/28/2009

Fund

Mission Bay Capital III

Mission Bay Capital II

QB3 Garage

Life Science Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Amount

$60M

$99M

$99M

Sources

1

10

10

10

Mission Bay Capital Partners & Customers

1 Partners and customers

Mission Bay Capital has 1 strategic partners and customers. Mission Bay Capital recently partnered with Bayer on .

Date

Type

Business Partner

Country

News Snippet

Sources

Partner

Germany

Bayer inks startup matchmaking deal with QB3, Mission Bay Capital

Bayer inks startup matchmaking deal with QB3 , Mission Bay Capital .

1

Date

Type

Partner

Business Partner

Country

Germany

News Snippet

Bayer inks startup matchmaking deal with QB3, Mission Bay Capital

Bayer inks startup matchmaking deal with QB3 , Mission Bay Capital .

Sources

1

Mission Bay Capital Team

2 Team Members

Mission Bay Capital has 2 team members, including current Managing Partner, Douglas Crawford.

Name

Work History

Title

Status

Douglas Crawford

Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Douglas Crawford

Subscribe to see more

Work History

Title

Managing Partner

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.